Company Henan Taloph Pharmaceutical Stock Co.,Ltd

Company Henan Taloph Pharmaceutical Stock Co.,Ltd

600222

CNE0000010L8

Pharmaceuticals

Equities

600222

CNE0000010L8

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Pharmaceuticals

HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
5.07 ^CNY	-2.31%		-4.16%	-17.29%

Apr. 25	Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	CI

HENANTALOPHPHARMACEUTICALSTOCKCO., LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The Company's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The Company distributes its products mainly within domestic market.

Number of employees: 2,353

CNY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Manufacturing 79.9 %	1,524	77.7 %	1,654	79.9 %	+8.53%
Drug Research and Development 16.6 %	322	16.4 %	343	16.6 %	+6.77%
Circulation of Medicines and Medicinal Materials 6.9 %	150	7.6 %	142	6.9 %	-4.98%
Inter-segment Elimination -3.7 %	-55	-2.8 %	-77	-3.7 %	+39.97%
Other 0.3 %	20	1.0 %	7	0.3 %	-66.02%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	1,961	100.0 %	2,070	100.0 %	+5.57%

Managers	Title	Age	Since
Jing Liang Li CEO	Chief Executive Officer	55	07-08-30
Hai Lin Zhao DFI	Director of Finance/CFO	49	-
Jian Chao Luo BRD	Director/Board Member	51	-

Members of the board	Title	Age	Since
Jing Liang Li CEO	Chief Executive Officer	55	07-08-30
Jian Chao Luo BRD	Director/Board Member	51	-
Xiao Hua Yin BRD	Director/Board Member	71	19-09-08
Zhi Xian Zhang CHM	Chairman	51	11-11-14
Liang Fang BRD	Director/Board Member	61	21-08-10
Si Liang Chen BRD	Director/Board Member	47	22-02-24
Jin Ge Chen BRD	Director/Board Member	46	22-02-24
Yu Min Liu BRD	Director/Board Member	68	22-02-24
Yi Kun Wang BRD	Director/Board Member	45	22-02-24
Rong Pu Li BRD	Director/Board Member	59	22-02-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	573,886,283	409,109,905 ( 71.29 %)	15,728,300 ( 2.741 %)	71.29 %

Name	Equities	%	Valuation
Penghua Fund Management Co., Ltd. 0.1611 %	913,000	0.1611 %	641 739 ¥
Huatai-PineBridge Fund Management Co., Ltd. 0.0252 %	142,700	0.0252 %	100 302 ¥
Yinhua Fund Management Co., Ltd. 0.0121 %	68,400	0.0121 %	48 078 ¥
China Asset Management Co., Ltd. 0.009773 %	55,400	0.009773 %	38 940 ¥
Bohai Huijin Securities Asset Management Co. Ltd. 0.004216 %	23,900	0.004216 %	16 799 ¥
Truvalue Asset Management Co. Ltd. 0.000706 %	4,000	0.000706 %	2 812 ¥

Henan Taloph Pharmaceutical Stock Co., Ltd.

8 Jinsuo Road Hi-Tech Industrial Development Zone

450001, Zhengzhou

+86 37 1679 93688

http://www.taloph.com

address Henan Taloph Pharmaceutical Stock Co.,Ltd(600222)

	1st Jan change	Capi.
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD	-17.29%	400M
ELI LILLY AND COMPANY	+38.24%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.64%	364B
MERCK & CO., INC.	+20.12%	332B
ABBVIE INC.	+5.12%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+8.68%	169B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals